$-0.97 EPS Expected for Flex Pharma, Inc. (FLKS)

February 15, 2018 - By Nellie Frank

 $ 0.97 EPS Expected for Flex Pharma, Inc. (FLKS)

Analysts expect Flex Pharma, Inc. (NASDAQ:FLKS) to report $-0.97 EPS on March, 14.They anticipate $0.49 EPS change or 102.08 % from last quarter’s $-0.48 EPS. After having $-0.54 EPS previously, Flex Pharma, Inc.’s analysts see 79.63 % EPS growth. The stock decreased 1.83% or $0.08 during the last trading session, reaching $4.3. About 33,715 shares traded. Flex Pharma, Inc. (NASDAQ:FLKS) has declined 70.24% since February 15, 2017 and is downtrending. It has underperformed by 86.94% the S&P500.

Flex Pharma, Inc. (NASDAQ:FLKS) Ratings Coverage

Among 6 analysts covering Flex Pharma (NASDAQ:FLKS), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Flex Pharma had 8 analyst reports since August 21, 2015 according to SRatingsIntel. The rating was downgraded by Zacks on Friday, August 21 to “Hold”. The rating was maintained by Jefferies with “Buy” on Tuesday, February 13. The rating was downgraded by Cantor Fitzgerald to “Hold” on Friday, October 14. The stock of Flex Pharma, Inc. (NASDAQ:FLKS) has “Hold” rating given on Tuesday, July 25 by Cantor Fitzgerald. The firm has “Hold” rating given on Wednesday, September 2 by Zacks. On Thursday, September 7 the stock rating was initiated by Roth Capital with “Buy”. The firm has “Buy” rating given on Thursday, August 3 by H.C. Wainwright.

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps and spasms associated with neurological conditions and exercise-associated muscle cramps in the United States. The company has market cap of $77.28 million. The firm operates through two divisions, Consumer Operations and Drug Development. It currently has negative earnings. The Company’s lead drug candidate includes FLX-787, a single molecule, chemically synthesized, and transient receptor potential ion channel activator, which is in exploratory Phase 2 clinical trial in Australia for the treatment of patients with multiple sclerosis and amyotrophic lateral sclerosis.

More notable recent Flex Pharma, Inc. (NASDAQ:FLKS) news were published by: Bostonglobe.com which released: “Flex Pharma chief executive steps down” on June 05, 2017, also Businesswire.com with their article: “Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of …” published on November 06, 2017, Marketwatch.com published: “Flex Pharma Inc.” on March 25, 2016. More interesting news about Flex Pharma, Inc. (NASDAQ:FLKS) were released by: Seekingalpha.com and their article: “Flex Pharma: What A Load Of Cramp” published on June 29, 2016 as well as Businesswire.com‘s news article titled: “Flex Pharma Names Dr. Roger Tung to Its Board of Directors” with publication date: October 31, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.